{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:56:14Z","timestamp":1761872174241,"version":"build-2065373602"},"reference-count":54,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.clml.2023.01.009","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T04:20:18Z","timestamp":1674188418000},"page":"232-237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["SOHO State of the Art Updates and Next Questions: New Targetable Pathways in Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"23","author":[{"given":"Bita","family":"Fakhri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4461-0970","authenticated-orcid":false,"given":"Alexey","family":"Danilov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.01.009_bib0001","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2023.01.009_bib0002","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Advances"},{"key":"10.1016\/j.clml.2023.01.009_bib0003","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib\u2013rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.009_bib0004","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"New Eng J Med"},{"key":"10.1016\/j.clml.2023.01.009_bib0005","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood-2021-153146","article-title":"Long-Term Results of Alliance A041202 show continued advantage of Ibrutinib-based regimens compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy","volume":"138","author":"Woyach","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.009_bib0006","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens versus Chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"The New Eng J Med"},{"key":"10.1016\/j.clml.2023.01.009_bib0007","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"New Eng J Med"},{"key":"10.1016\/j.clml.2023.01.009_bib0008","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2015","journal-title":"New Eng J Med"},{"key":"10.1016\/j.clml.2023.01.009_bib0009","doi-asserted-by":"crossref","DOI":"10.1177\/2040620721989588","article-title":"The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia","volume":"12","author":"Gordon","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2023.01.009_bib0010","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1182\/blood.2019004205","article-title":"Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax","volume":"135","author":"Blombery","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.009_bib0011","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11912-020-0874-3","article-title":"Cell death pathways in Lymphoid malignancies","volume":"22","author":"Fletcher","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.clml.2023.01.009_bib0012","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","article-title":"BTK(C481S)-mediated resistance to Ibrutinib in Chronic Lymphocytic Leukemia","volume":"35","author":"Woyach","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.01.009_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.689472","article-title":"Resistance Mutations to BTK inhibitors originate from the NF-\u03baB but not from the PI3K-RAS-MAPK Arm of the B cell receptor signaling pathway","volume":"12","author":"Smith","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2023.01.009_bib0014","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2016-06-719294","article-title":"Clonal evolution leading to ibrutinib resistance in Chronic Lymphocytic Leukemia","volume":"129","author":"Ahn","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.009_bib0015","doi-asserted-by":"crossref","first-page":"11589","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with Chronic Lymphocytic Leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2023.01.009_bib0016","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/bloodadvances.2016003632","article-title":"Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL","volume":"1","author":"Kadri","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.01.009_bib0017","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/17474086.2018.1435268","article-title":"Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?","volume":"11","author":"Lampson","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2023.01.009_bib0018","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of Ibrutinib therapy discontinuation and outcomes in patients with Chronic Lymphocytic Leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2023.01.009_bib0019","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.01.009_bib0020","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2023.01.009_bib0021","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1182\/blood-2019-127260","article-title":"Final results of phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or Refractory B-Cell Lymphoid malignancies","volume":"134","author":"Woyach","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.009_bib0022","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41419-022-04684-1","article-title":"Dual BTK\/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma","volume":"13","author":"Thieme","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.clml.2023.01.009_bib0023","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1182\/blood-2006-03-012021","article-title":"B-cell receptor signaling in chronic Lymphocytic Leukemia cells is regulated by overexpressed active protein kinase CbetaII","volume":"109","author":"Abrams","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.009_bib0024","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.3390\/cancers14236006","article-title":"PKC\u03b2 facilitates Leukemogenesis in Chronic Lymphocytic Leukaemia by promoting constitutive BCR-mediated signalling","volume":"14","author":"Hay","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2023.01.009_bib0025","doi-asserted-by":"crossref","first-page":"9857","DOI":"10.1182\/blood-2022-168391","article-title":"MS-553, a Selective PKC-\u00df inhibitor inhibits BCR signaling and synergizes with Venetoclax for the treatment of high risk CLL","volume":"140","author":"Singh","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.009_bib0026","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.01.009_bib0027","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12943-021-01434-3","article-title":"Proteolysis-targeting chimeras (PROTACs) in cancer therapy","volume":"21","author":"Li","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.clml.2023.01.009_bib0028","doi-asserted-by":"crossref","first-page":"TPS7581","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7581","article-title":"A first-in-human phase 1 trial of NX-2127, a first-in-class oral BTK degrader with IMiD-like activity, in patients with relapsed and refractory B-cell malignancies","volume":"40","author":"Mato","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.01.009_bib0029","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2022-164772","article-title":"NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton's Tyrosine Kinase-targeted protein degrader, in patients with relapsed or refractory chronic Lymphocytic Leukemia and B-Cell Malignancies","volume":"140","author":"Mato","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.009_bib0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/cpt.553","article-title":"Targeting BCL2 with BH3 mimetics: basic science and clinical application of Venetoclax in Chronic Lymphocytic Leukemia and related B Cell malignancies","volume":"101","author":"Roberts","year":"2017","journal-title":"Clin Pharmacol Therap"},{"key":"10.1016\/j.clml.2023.01.009_bib0031","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with Chronic Lymphocytic Leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"New Eng J Med"},{"key":"10.1016\/j.clml.2023.01.009_bib0032","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013Rituximab in relapsed or refractory Chronic Lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"New Eng J Med"},{"key":"10.1016\/j.clml.2023.01.009_bib0033","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.009_bib0034","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val Mutation in BCL2 confers resistance to Venetoclax in patients with progressive Chronic Lymphocytic Leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2023.01.009_bib0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.01.009_bib0036","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2023.01.009_bib0037","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-21-0464","article-title":"Pharmacologic targeting of Mcl-1 Induces Mitochondrial dysfunction and apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX-Dependent manner","volume":"27","author":"Liu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.01.009_bib0038","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a Selective MCL1 Inhibitor, is effective in Hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.clml.2023.01.009_bib0039","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-19-1397","article-title":"AMG-176, an Mcl-1 Antagonist, shows preclinical efficacy in Chronic Lymphocytic Leukemia","volume":"26","author":"Yi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.01.009_bib0040","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.clml.2023.01.009_bib0041","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.3324\/haematol.2020.252130","article-title":"Inhibition of the anti-apoptotic protein MCL-1 severely suppresses human hematopoiesis","volume":"106","author":"Bohler","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2023.01.009_bib0042","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic Lymphocytic Leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.01.009_bib0043","doi-asserted-by":"crossref","first-page":"6535","DOI":"10.1158\/1078-0432.CCR-20-0863","article-title":"AZD4320, a dual inhibitor of Bcl-2 and Bcl-xL, induces Tumor regression in Hematologic Cancer models without dose-limiting Thrombocytopenia","volume":"26","author":"Balachander","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2023.01.009_bib0044","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/hematology.2021000234","article-title":"Is there a role for anti-CD20 antibodies in CLL?","volume":"2021","author":"Shah","year":"2021","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2023.01.009_bib0045","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.3389\/fimmu.2018.02285","article-title":"BAFF and BAFF-Receptor in B Cell Selection and Survival","volume":"9","author":"Smulski","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2023.01.009_bib0046","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1182\/bloodadvances.2018025684","article-title":"Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib","volume":"3","author":"McWilliams","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.01.009_bib0047","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1182\/blood-2021-147775","article-title":"Investigating the Addition of Ianalumab (VAY736) to Ibrutinib in patients with Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy: results from a Phase Ib Study","volume":"138","author":"Rogers","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.009_bib0048","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1080\/10428194.2021.1964020","article-title":"Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor","volume":"62","author":"Staber","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2023.01.009_bib0049","doi-asserted-by":"crossref","first-page":"951-9 e3","DOI":"10.1016\/j.stem.2018.05.018","article-title":"Phase I Trial: Cirmtuzumab Inhibits ROR1 signaling and stemness signatures in patients with Chronic Lymphocytic Leukemia","volume":"22","author":"Choi","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.clml.2023.01.009_bib0050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.01.009_bib0051","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood.2021011895","article-title":"Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL","volume":"139","author":"Siddiqi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.009_bib0052","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.01.009_bib0053","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2021-146563","article-title":"Subcutaneous Epcoritamab in patients with relapsed\/refractory Chronic Lymphocytic Leukemia: preliminary results from the Epcore CLL-1 Trial","volume":"138","author":"Kater","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.01.009_bib0054","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1182\/blood-2022-158298","article-title":"Subcutaneous Epcoritamab in patients with Richter's syndrome: early results from Phase 1b\/2 Trial (EPCORE CLL-1)","volume":"140","author":"Kater","year":"2022","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023000216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:36Z","timestamp":1761871296000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023000216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2152265023000216"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.01.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions: New Targetable Pathways in Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}